Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

CORIMUNO-SARI-1 (non ICU)
 
NCT04324073
RCTsarilumabstandard of careCOVID 19 hospitalizedsome concern
68/80 inconclusive
  • inconclusive 1 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
  • inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
Declercq J (COV-AID)
 
NCT04330638
RCTtocilizumab standard of careCOVID 19 hospitalizedlow
114/115 inconclusive
    RCT-TCZ-COVID-19
     
    NCT04346355
    RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
    60/66 inconclusive
      RECOVERY
       
      NCT04381936
      RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
      2022/2094 conclusif
      • demonstrated 15 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 15 % decrease in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
      Rutgers RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
      174/180 suggested
      • inconclusive 41 % decrease in death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 35 % decrease in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
      Soin AS (COVINTOC)
       
      CTRI/2020/05/025369
      RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
      90/90 inconclusive
        Dongsheng Wang
         
        ChiCTR2000029765
        RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
        33/32 safety concern
        • statistically significant 8.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
        EMPACTA
         
        NCT04372186
        RCTtocilizumab placeboCOVID 19 hospitalizedsome concern
        259/129 conclusif
        • demonstrated 44 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
        • suggested 45 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
        EU-CTR2020-001375-32 (PreToVid) unpublished
         
        EU-CTR2020-001375-32
        RCTtocilizumab standard of careCOVID 19 hospitalizedlow
        174/180 inconclusive
          EU-CTR2020-001748-24 (ImmCoVA) unpublished
           
          EU-CTR2020-001748-24
          RCTtocilizumab standard of careCOVID 19 hospitalizedlow
          22/27 inconclusive
            NCT04412772 (ARCHITECTS) unpublished
             
            NCT04412772
            RCTtocilizumab placeboCOVID 19 hospitalizedlow
            10/11 inconclusive
              NCT04434717 (COVITOZ-1 single dose plus two doses) unpublished
               
              NCT04434717
              RCTtocilizumab standard of careCOVID 19 hospitalizedlow
              17/9 inconclusive
                NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg) unpublished
                 
                NCT04479358
                RCTtocilizumab standard of careCOVID 19 hospitalizedlow
                20/8 inconclusive
                  NCT04577534 (COVIDSTORM) unpublished
                   
                  NCT04577534
                  RCTtocilizumab standard of careCOVID 19 hospitalizedlow
                  26/13 inconclusive

                    COVID 19 all comers meta-analysis

                    BACC Bay Tocilizumab Trial
                     
                    NCT04356937
                    RCTtocilizumab placeboCOVID 19 all comerslow
                    161/81 inconclusive
                    • inconclusive 17 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias

                    COVID-19 severe or critically meta-analysis

                    REMAP-CAP (tocilizumab)
                     
                    NCT02735707
                    RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                    353/402 conclusif
                    • suggested 30 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
                    • demonstrated 64 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
                    Rosas (REMDACTA)
                     
                    NCT04409262
                    RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
                    434/215 inconclusive
                    • inconclusive 3 % decrease in hospital discharge (PE) with a moderate degree of certainty due to some concern in risk of bias
                    Talaschian
                     
                    IRCT20081027001411N4
                    RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                    20/20 inconclusive
                      Veiga
                       
                      NCT04403685
                      RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                      65/64 safety concern
                      • safety concern with 1.7-fold increase in deaths,death D28 (not statistically significant)
                      • inconclusive 54 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
                      CORIMUNO-TOCI-1 (Group 1)
                       
                      NCT04331808
                      RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                      64/67 inconclusive
                        CORIMUNO-TOCI-ICU (Group 2)
                         
                        NCT04331808
                        RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                        49/43 inconclusive
                          COVACTA (Rosas)
                           
                          NCT04320615
                          RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
                          301/151 suggested
                          • inconclusive 19 % increase in clinical improvement,clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
                          16 studies excluded by filtering options (4 RCT / 12 OBS)

                          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).